Student Hosted Colloquia Seminar: Dr. Jay Bradner, Amgen
About the Seminar
Therapeutic Modularity
About the Speaker
James (Jay) E. Bradner, M.D. is an American Physician-Scientist and Drug Developer.
Presently, he serves as Executive Vice President for Research & Development and Chief Scientific Officer for Amgen (Thousand Oaks, California). In this role, he leads an integrated global discovery research, early and confirmatory clinical development organization across four therapeutic Areas and two therapeuticmodalities. Additionally, he serves on the CEO Staff as an Amgen executive. A focus of Amgen R&D is the development of definitive medicines for serious illnesses, incisively invoking human genetics to discover new targets and creatively leveraging multi-specific platforms to short-circuit disease processes. Within and beyond Amgen, he has contributed to the regulatory approval of 25 medicines.
Immediately before joining Amgen, Dr. Bradner enjoyed a return to clinical service as a Stem Cell Transplant physician at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital, teaching at Harvard Business School and MIT, and advising Blackstone Financial Group and the FNIH.He has also served as President of the Novartis Institutes for BioMedical Research (NIBR) and as a member of the Executive Committee of Novartis, from 2016 to 2022. In this role, he led global Research and early Drug Development for internal and external innovation, through NIBR Business Development and the Novartis Venture Fund. In his seven years of leadership, NIBR innovated 80 development candidates, filed 75 INDs and reported out 90 positive proof-of-concept studies inhuman clinical investigation.
Earlier in his career, Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus of the Bradner laboratory had been the study of BET bromodomain proteins and their function in gene control, innovating chemical probes and investigational drugs to study and treat cancer. Further, the Bradner laboratory pioneered an all-chemical strategy for targeted protein degradation, broadly used today in investigational therapeutics. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 250 scientific publications and 50 United States patent applications.
Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed residency in Medicine at Brigham & Women's Hospital, fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and postdoctoral training in Chemistry and Chemical Biology at Harvard University (Prof. Stuart Schreiber).
Personally, Jay is a native Midwesterner married to Jennifer Antolini Bradner, a corporate attorney. They have three children, Jack (16), Merritt and Belen (12). Interests include sports (cycling, tennis, golf, hockey and surfing), fishing and playing guitar.